5H0V
| Crystal structure of H88A mutated human transthyretin | Descriptor: | (4S)-2-METHYL-2,4-PENTANEDIOL, MAGNESIUM ION, Transthyretin | Authors: | Yokoyama, T, Hanawa, Y, Obita, T, Mizuguchi, M. | Deposit date: | 2016-10-07 | Release date: | 2017-06-14 | Last modified: | 2024-03-20 | Method: | X-RAY DIFFRACTION (1.58 Å) | Cite: | Stability and crystal structures of His88 mutant human transthyretins FEBS Lett., 591, 2017
|
|
5H0W
| Crystal structure of H88F mutated human transthyretin | Descriptor: | SULFATE ION, Transthyretin | Authors: | Yokoyama, T, Hanawa, Y, Obita, T, Mizuguchi, M. | Deposit date: | 2016-10-07 | Release date: | 2017-06-14 | Last modified: | 2024-03-20 | Method: | X-RAY DIFFRACTION (1.904 Å) | Cite: | Stability and crystal structures of His88 mutant human transthyretins FEBS Lett., 591, 2017
|
|
5H0Y
| Crystal structure of H88Y mutated human transthyretin | Descriptor: | CHLORIDE ION, SULFATE ION, Transthyretin | Authors: | Yokoyama, T, Hanawa, Y, Obita, T, Mizuguchi, M. | Deposit date: | 2016-10-07 | Release date: | 2017-06-14 | Last modified: | 2024-03-20 | Method: | X-RAY DIFFRACTION (1.8 Å) | Cite: | Stability and crystal structures of His88 mutant human transthyretins FEBS Lett., 591, 2017
|
|
4PWF
| Crystal structure of V30M mutant human transthyretin complexed with ferulic acid phenethyl ester | Descriptor: | 2-phenylethyl (2E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate, Transthyretin | Authors: | Yokoyama, T, Kosaka, Y, Mizuguchi, M. | Deposit date: | 2014-03-20 | Release date: | 2014-11-26 | Last modified: | 2023-11-08 | Method: | X-RAY DIFFRACTION (1.6 Å) | Cite: | Inhibitory Activities of Propolis and Its Promising Component, Caffeic Acid Phenethyl Ester, against Amyloidogenesis of Human Transthyretin J.Med.Chem., 57, 2014
|
|
4PWH
| Crystal structure of V30M mutant human transthyretin complexed with caffeic acid 1,1-dimethylallyl ester | Descriptor: | 3-methylbut-2-en-1-yl (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoate, CALCIUM ION, Transthyretin | Authors: | Yokoyama, T, Kosaka, Y, Mizuguchi, M. | Deposit date: | 2014-03-20 | Release date: | 2014-11-26 | Last modified: | 2023-11-08 | Method: | X-RAY DIFFRACTION (1.798 Å) | Cite: | Inhibitory Activities of Propolis and Its Promising Component, Caffeic Acid Phenethyl Ester, against Amyloidogenesis of Human Transthyretin J.Med.Chem., 57, 2014
|
|
4PWI
| Crystal structure of V30M mutant human transthyretin complexed with rosmarinic acid | Descriptor: | (2R)-3-(3,4-dihydroxyphenyl)-2-{[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy}propanoic acid, Transthyretin | Authors: | Yokoyama, T, Kosaka, Y, Mizuguchi, M. | Deposit date: | 2014-03-20 | Release date: | 2014-11-26 | Last modified: | 2023-11-08 | Method: | X-RAY DIFFRACTION (1.494 Å) | Cite: | Inhibitory Activities of Propolis and Its Promising Component, Caffeic Acid Phenethyl Ester, against Amyloidogenesis of Human Transthyretin J.Med.Chem., 57, 2014
|
|
4PWE
| |
4PWJ
| Crystal structure of V30M mutant human transthyretin complexed with nordihydroguaiaretic acid | Descriptor: | 4-[(2R,3S)-3-[(3,4-DIHYDROXYPHENYL)METHYL]-2-METHYLBUTYL]BENZENE-1,2-DIOL, Transthyretin | Authors: | Yokoyama, T, Kosaka, Y, Mizuguchi, M. | Deposit date: | 2014-03-20 | Release date: | 2014-11-26 | Last modified: | 2023-11-08 | Method: | X-RAY DIFFRACTION (1.55 Å) | Cite: | Inhibitory Activities of Propolis and Its Promising Component, Caffeic Acid Phenethyl Ester, against Amyloidogenesis of Human Transthyretin J.Med.Chem., 57, 2014
|
|
4PWG
| Crystal structure of V30M mutant human transthyretin complexed with caffeic acid ethyl ester | Descriptor: | CALCIUM ION, Transthyretin, ethyl (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoate | Authors: | Yokoyama, T, Kosaka, Y, Mizuguchi, M. | Deposit date: | 2014-03-20 | Release date: | 2014-11-26 | Last modified: | 2023-11-08 | Method: | X-RAY DIFFRACTION (1.798 Å) | Cite: | Inhibitory Activities of Propolis and Its Promising Component, Caffeic Acid Phenethyl Ester, against Amyloidogenesis of Human Transthyretin J.Med.Chem., 57, 2014
|
|
4PWK
| Crystal structure of V30M mutant human transthyretin complexed with dihydroguaiaretic acid | Descriptor: | 4,4'-[(2R,3R)-2,3-dimethylbutane-1,4-diyl]bis(2-methoxyphenol), Transthyretin | Authors: | Yokoyama, T, Kosaka, Y, Mizuguchi, M. | Deposit date: | 2014-03-20 | Release date: | 2014-11-26 | Last modified: | 2023-11-08 | Method: | X-RAY DIFFRACTION (1.59 Å) | Cite: | Inhibitory Activities of Propolis and Its Promising Component, Caffeic Acid Phenethyl Ester, against Amyloidogenesis of Human Transthyretin J.Med.Chem., 57, 2014
|
|
4QRF
| Crystal structure of V30M mutant human transthyretin complexed with caffeic acid phenethyl ester | Descriptor: | 2-phenylethyl (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoate, Transthyretin | Authors: | Yokoyama, T, Kosaka, Y, Mizuguchi, M. | Deposit date: | 2014-06-30 | Release date: | 2014-11-26 | Last modified: | 2023-11-08 | Method: | X-RAY DIFFRACTION (1.8 Å) | Cite: | Inhibitory Activities of Propolis and Its Promising Component, Caffeic Acid Phenethyl Ester, against Amyloidogenesis of Human Transthyretin J.Med.Chem., 57, 2014
|
|
3J0E
| Models for the T. thermophilus ribosome recycling factor and the E. coli elongation factor G bound to the E. coli post-termination complex | Descriptor: | 30S ribosomal protein S12, Elongation factor G, Ribosome-recycling factor, ... | Authors: | Yokoyama, T, Shaikh, T.R, Iwakura, N, Kaji, H, Kaji, A, Agrawal, R.K. | Deposit date: | 2011-06-29 | Release date: | 2012-04-25 | Last modified: | 2024-02-21 | Method: | ELECTRON MICROSCOPY (9.9 Å) | Cite: | Structural insights into initial and intermediate steps of the ribosome-recycling process. Embo J., 31, 2012
|
|
3J0D
| Models for the T. thermophilus ribosome recycling factor bound to the E. coli post-termination complex | Descriptor: | 30S ribosomal protein S12, 50S ribosomal protein L11, Ribosome-recycling factor, ... | Authors: | Yokoyama, T, Shaikh, T.R, Iwakura, N, Kaji, H, Kaji, A, Agrawal, R.K. | Deposit date: | 2011-06-29 | Release date: | 2012-04-25 | Last modified: | 2024-02-21 | Method: | ELECTRON MICROSCOPY (11.1 Å) | Cite: | Structural insights into initial and intermediate steps of the ribosome-recycling process. Embo J., 31, 2012
|
|
5AYT
| Crystal structure of transthyretin in complex with L6 | Descriptor: | 2-oxidanyl-6-(phenylcarbonyl)benzo[de]isoquinoline-1,3-dione, Transthyretin | Authors: | Yokoyama, T, Mizuguchi, M, Kai, H. | Deposit date: | 2015-09-03 | Release date: | 2016-01-20 | Last modified: | 2024-03-20 | Method: | X-RAY DIFFRACTION (1.4 Å) | Cite: | Structural stabilization of transthyretin by a new compound, 6-benzoyl-2-hydroxy-1H-benzo[de]isoquinoline-1,3(2H)-dione J. Pharmacol. Sci., 129, 2015
|
|
8IG1
| Crystal structure of wild-type transthyretin in complex with rafoxanide | Descriptor: | SODIUM ION, Transthyretin, ~{N}-[3-chloranyl-4-(4-chloranylphenoxy)phenyl]-3,5-bis(iodanyl)-2-oxidanyl-benzamide | Authors: | Yokoyama, T. | Deposit date: | 2023-02-20 | Release date: | 2023-08-16 | Last modified: | 2023-11-15 | Method: | X-RAY DIFFRACTION (1.451 Å) | Cite: | Rafoxanide, a salicylanilide anthelmintic, interacts with human plasma protein transthyretin. Febs J., 290, 2023
|
|
6IN0
| Crystal structure of EphA3 in complex with 18-Crown-6 | Descriptor: | 1,4,7,10,13,16-HEXAOXACYCLOOCTADECANE, CHLORIDE ION, Ephrin type-A receptor 3 | Authors: | Yokoyama, T, Kosaka, Y, Matsumoto, K, Kitakami, R, Nabeshima, Y, Mizuguchi, M. | Deposit date: | 2018-10-24 | Release date: | 2019-10-30 | Last modified: | 2024-03-27 | Method: | X-RAY DIFFRACTION (1.501 Å) | Cite: | Crown Ethers as Transthyretin Amyloidogenesis Inhibitor To Be Published
|
|
6IMZ
| Crystal structure of MTH1 in complex with 18-Crown-6 | Descriptor: | 1,4,7,10,13,16-HEXAOXACYCLOOCTADECANE, 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-amine, 7,8-dihydro-8-oxoguanine triphosphatase, ... | Authors: | Yokoyama, T, Kosaka, Y, Matsumoto, K, Kitakami, R, Nabeshima, Y, Mizuguchi, M. | Deposit date: | 2018-10-24 | Release date: | 2019-10-30 | Last modified: | 2024-03-27 | Method: | X-RAY DIFFRACTION (2.1 Å) | Cite: | Crown Ethers as Transthyretin Amyloidogenesis Inhibitor To Be Published
|
|
6IMX
| Crystal structure of V30M mutated transthyretin in complex with 18-Crown-6 | Descriptor: | 1,4,7,10,13,16-HEXAOXACYCLOOCTADECANE, Transthyretin | Authors: | Yokoyama, T, Kosaka, Y, Matsumoto, K, Kitakami, R, Nabeshima, Y, Mizuguchi, M. | Deposit date: | 2018-10-24 | Release date: | 2019-03-13 | Last modified: | 2024-03-27 | Method: | X-RAY DIFFRACTION (1.602 Å) | Cite: | Crown Ethers as Transthyretin Amyloidogenesis Inhibitors. J. Med. Chem., 62, 2019
|
|
6IN4
| Crystal structure of apo DAPK1 in the presence of 18-crown-6 | Descriptor: | Death-associated protein kinase 1, SULFATE ION | Authors: | Yokoyama, T, Kosaka, Y, Matsumoto, K, Kitakami, R, Nabeshima, Y, Mizuguchi, M. | Deposit date: | 2018-10-24 | Release date: | 2019-10-30 | Last modified: | 2024-03-27 | Method: | X-RAY DIFFRACTION (1.8 Å) | Cite: | Crown Ethers as Transthyretin Amyloidogenesis Inhibitor To Be Published
|
|
6IN3
| Crystal structure of DOT1L in complex with 18-Crown-6 | Descriptor: | 1,4,7,10,13,16-HEXAOXACYCLOOCTADECANE, Histone-lysine N-methyltransferase, H3 lysine-79 specific, ... | Authors: | Yokoyama, T, Kosaka, Y, Matsumoto, K, Kitakami, R, Nabeshima, Y, Mizuguchi, M. | Deposit date: | 2018-10-24 | Release date: | 2019-10-30 | Last modified: | 2024-03-27 | Method: | X-RAY DIFFRACTION (2.3 Å) | Cite: | Crown Ethers as Transthyretin Amyloidogenesis Inhibitor To Be Published
|
|
6IN1
| Crystal structure of the first bromodomain of BRD4 in complex with 18-Crown-6 | Descriptor: | 1,4,7,10,13,16-HEXAOXACYCLOOCTADECANE, Bromodomain-containing protein 4, N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-6,7-dihydro-5H-benzo[d]heptalen-7-yl]ethanamide, ... | Authors: | Yokoyama, T, Kosaka, Y, Matsumoto, K, Kitakami, R, Nabeshima, Y, Mizuguchi, M. | Deposit date: | 2018-10-24 | Release date: | 2019-10-30 | Last modified: | 2024-03-27 | Method: | X-RAY DIFFRACTION (1.5 Å) | Cite: | Crown Ethers as Transthyretin Amyloidogenesis Inhibitor To Be Published
|
|
6IMY
| Crystal structure of V30M mutated transthyretin in complex with 4'-caroboxybenzo-18-Crown-6 | Descriptor: | 2,3,5,6,8,9,11,12,14,15-decahydro-1,4,7,10,13,16-benzohexaoxacyclooctadecine-18-carboxylic acid, Transthyretin | Authors: | Yokoyama, T, Kosaka, Y, Matsumoto, K, Kitakami, R, Nabeshima, Y, Mizuguchi, M. | Deposit date: | 2018-10-24 | Release date: | 2019-03-13 | Last modified: | 2024-03-27 | Method: | X-RAY DIFFRACTION (1.501 Å) | Cite: | Crown Ethers as Transthyretin Amyloidogenesis Inhibitors. J. Med. Chem., 62, 2019
|
|
6IN2
| Crystal structure of BRD1 in complex with 18-Crown-6 | Descriptor: | 1,4,7,10,13,16-HEXAOXACYCLOOCTADECANE, ACETATE ION, Bromodomain-containing protein 1 | Authors: | Yokoyama, T, Kosaka, Y, Matsumoto, K, Kitakami, R, Nabeshima, Y, Mizuguchi, M. | Deposit date: | 2018-10-24 | Release date: | 2019-10-30 | Last modified: | 2024-03-27 | Method: | X-RAY DIFFRACTION (1.75 Å) | Cite: | Crown Ethers as Transthyretin Amyloidogenesis Inhibitor To Be Published
|
|
3D6L
| |
8IE8
| Crystal structure of DAPK1 in complex with isorhapontigenin | Descriptor: | 5-[(~{E})-2-(3-methoxy-4-oxidanyl-phenyl)ethenyl]benzene-1,3-diol, Death-associated protein kinase 1, SULFATE ION | Authors: | Yokoyama, T. | Deposit date: | 2023-02-15 | Release date: | 2023-05-24 | Last modified: | 2023-10-04 | Method: | X-RAY DIFFRACTION (1.75 Å) | Cite: | Characterization of the molecular interactions between resveratrol derivatives and death-associated protein kinase 1. Febs J., 290, 2023
|
|